




1/25

FIGURE 1



A**B**

2/25

FIGURE 1 - *continued*


3/25

FIGURE 2






4/25

FIGURE 3



5/25

FIGURE 4




B

FIGURE 5


WY-14643 μ M	0	10	30	Specific competitor	Non-specific competitor	
						← p50/p65
						← Oct-1
						← Sp-1

B

							Specific competitor	Non-specific competitor
1 ng/ml IL-1 β	-	+	+	+	+	+	+	+
WY-14643 μ M	-	-	-	-	50	10	-	-
Troglitazone μ M	-	-	50	10	-	-	-	-




← p65/p65
← p50/p65



← Oct-1

7/25


FIGURE 6




8/25

FIGURE 7

A




B



9/25



FIGURE 8






- NS
- ▨ IL-1b
- ▤ 15uM 15dPGJ2 + IL-1b
- ▥ 30uM 15dPGJ2 + IL-1b
- ▧ 90uM PGA1 + IL-1b
- ▩ 180uM PGA1 + IL-1b
- 30uM troglitazone + IL-1b
- ▬ 30uM WY-14643 + IL-1b

10/25

FIGURE 9




*11/25***FIGURE 10**


*12/25***FIGURE 11**

13/25

FIGURE 12





A



B


14/25

FIGURE 13



15/25


FIGURE 14




16/25

FIGURE 15


A.



B.




17/25

FIGURE 15 - *continued*

C.


18/25

FIGURE 16




19/25

FIGURE 17




A



B

20/25

FIGURE 18



21/25

FIGURE 19







FIGURE 20




23/25

FIGURE 21

A.




B.



24/25

FIGURE 22



25/25

FIGURE 23

